An observational study in Osteoarthritis, sponsored by Bayer. Completed at 2 sites in Russian Federation. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-14.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Osteoarthritis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Russian Federation.
Among the 20 studies in Osteoarthritis with a site in Russian Federation, this one is the only one that started in 2017, is one of 3 observational ones, and was the 11th registered.
2,977 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →None of the 20 studies in Osteoarthritis with a site in Russian Federation is open now. The open studies under Osteoarthritis, anywhere →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 5 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,102 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.
Median enrollment 144 across the 17 interventional studies, 3,569 across the 3 observational. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 20 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Osteoarthritis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate how a long-term treatment with Theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient satisfaction with treatment.
Other information that is planned for evaluation in this study includes consumption of Theraflex, intake of analgesics for joint pain relief and description of basic patient characteristics such as age, weight and body mass index and others.
Patient who will be made aware about the study either by the treating physician OR by a pharmacist where a patient is purchasing Theraflex
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
Drug: Theraflex, BAY 874017
Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
Drug: Theraflex, BAY 874017
The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
Changes in the Pain Intensity Subscale
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.
Time frame: From enrollment up to 64 weeks
Changes in Other Symptoms Subscale
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.
Time frame: From enrollment up to 64 weeks
Change in Functional Activity of the Joint Subscale
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.
Time frame: From enrollment up to 64 weeks
Change in Life Quality Subscale
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.
Time frame: From enrollment up to 64 weeks
Number of Participant Compliance With Drug Utilization of Theraflex
Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.
Time frame: From enrollment up to 64 weeks
Change in Patient Satisfaction Assessment
Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied
Time frame: From enrollment up to 64 weeks
Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA)
Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.
Time frame: From enrollment up to 64 weeks
Number of Participant With Concomitant Therapy of the Target Joint Osteoarthritis (OA) Used After the Completion of Treatment With Theraflex
Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.
Time frame: From enrollment up to 64 weeks
Study was conducted at 51 centers in Russian Federation, between 20-Nov-2017 (first participant first visit) and 13-Jul-2020 (Database clean). The Primary Completion date is 18-Mar-2020 (last participant last visit)
| Milestone | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| Started | 824 | 278 |
| Completed | 794 | 270 |
| Not completed | 30 | 8 |
| Withdrew: Other reason | 1 | 1 |
| Withdrew: Switching to a different disease-modifying delayed-release drug sysadoa | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Lost to follow-up | 26 | 7 |
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Pain intensity is one subscale of KOOS and HOOS questionnaire, each pain intensity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS pain intensity subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS pain intensity subscale results calculation used a similar method.
| Scores on a scale | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| From Visit 1(enrollment) to Visit 2 (Week 16-24) | 18.07 ± 16.900 | 15.59 ± 16.686 |
| From Visit 1(enrollment) toVisit 3 (Week 36-44) | 20.92 ± 17.946 | 20.06 ± 17.686 |
| From Visit 1(enrollment) toVisit 4 (Week 56-64) | 22.87 ± 18.815 | 22.81 ± 19.550 |
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Other symptoms is one subscale of KOOS and HOOS questionnaire, each other symptoms question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS other symptoms subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS other symptoms subscale results calculation used a similar method.
| Scores on a scale | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| From Visit 1(enrollment) to Visit 2 (Week 16-24) | 15.48 ± 17.465 | 12.65 ± 16.937 |
| From Visit 1(enrollment) toVisit 3 (Week 36-44) | 18.87 ± 18.685 | 17.10 ± 17.811 |
| From Visit 1(enrollment) toVisit 4 (Week 56-64) | 20.78 ± 19.330 | 19.93 ± 20.318 |
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Functional activity is one subscale of KOOS and HOOS questionnaire, each functional activity question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS functional activity subscale were calculated by converting value of all subscale questions to KOOS-Physical Short form score. Results score is from 0 to 100, 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS functional activity subscale results used a similar method with HOOS-Physical Short form.
| Scores on a scale | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| From Visit 1(enrollment) to Visit 2 (Week 16-24) | 10.98 ± 11.831 | 13.26 ± 15.729 |
| From Visit 1(enrollment) to Visit 3 (Week 36-44) | 14.26 ± 13.708 | 16.41 ± 16.584 |
| From Visit 1(enrollment) to Visit 4 (Week 56-64) | 16.60 ± 14.503 | 18.77 ± 18.041 |
KOA patients used KOOS questionnaire, HOA patients used HOOS questionnaire. Life quality is one subscale of KOOS and HOOS questionnaire, each life quality question provides standard answer options: 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme. The results for KOOS life quality subscale were calculated as \[100 - (mean value of all subscale questions \* 100) / 4\]. Results score is from 0 to 100. 100 indicating no symptoms and 0 indicating extreme symptoms. HOOS life quality subscale results calculation used a similar method.
| Scores on a scale | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| From Visit 1(enrollment) to Visit 2 (Week 16-24) | 16.29 ± 17.888 | 14.25 ± 18.068 |
| From Visit 1(enrollment) to Visit 3 (Week 36-44) | 20.79 ± 19.625 | 18.82 ± 18.915 |
| From Visit 1(enrollment) to Visit 4 (Week 56-64) | 24.87 ± 21.055 | 22.71 ± 21.444 |
Drug utilization of Theraflex as reported by the patient to their physician. Administration duration categories are: 1.patients receiving Theraflex up to 1 month inclusive; 2.patients taking Theraflex during 1 to 3 months; 3.patients taking Theraflex during 3 to 6 months; 4. patients taking Theraflex during more than 6 months. Investigators assessed compliance with the recommendations for the duration of Theraflex.
| Participant | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| Participant followed the recommendations | 753 | 253 |
| Participant not followed the recommendations | 59 | 21 |
| No data available | 12 | 4 |
Patient satisfaction questionnaire was filled out during the visit to a doctor. A patient assessed treatment satisfaction against the Likert response scale : 5-very satisfied, 4-Satisfied, 3- No answer, 2-Dissatisfied, 1-very dissatisfied
| Scores on a scale | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| From Visit 1(enrollment) to Visit 2 (Week 16-24) | 0.8 ± 0.84 | 0.8 ± 0.87 |
| From Visit 1(enrollment) to Visit 3 (Week 36-44) | 0.8 ± 0.89 | 0.9 ± 0.81 |
| From Visit 1(enrollment) to Visit 4 (Week 56-64) | 0.9 ± 0.94 | 0.9 ± 0.94 |
Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.
| Participant | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| Symptomatic therapy with analgesics for the target joint OA | 274 | 103 |
| Other drug treatment for pain syndrome of the target joint OA | 84 | 25 |
| Other therapy for the target joint OA | 36 | 4 |
Concomitant therapy of the target joint osteoarthritis (OA) by choosing any of the following categories: 'Symptomatic therapy with analgesics for the target joint OA', 'Other drug treatment for pain syndrome of the target joint OA', 'Other therapy for the target joint OA'.
| Participant | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) |
|---|---|---|
| Symptomatic therapy with analgesics for the target joint OA | 20 | 5 |
| Other drug treatment for pain syndrome of the target joint OA | 11 | 6 |
| Other therapy for the target joint OA | 9 | 0 |
Collected over After initial administration of Theraflex up to 64 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants With Stage I-III Hip Osteoarthritis (HOA) | 0/278 (0%) | 6/278 (2.2%) | 28/278 (10.1%) |
| Participants With Stage I-III Knee Osteoarthritis (KOA) | 1/824 (0.1%) | 8/824 (1%) | 55/824 (6.7%) |
| Event | Participants With Stage I-III Hip Osteoarthritis (HOA) | Participants With Stage I-III Knee Osteoarthritis (KOA) |
|---|---|---|
| Angina pectorisCardiac disorders | 1/278 | 0/824 |
| Atrial fibrillationCardiac disorders | 1/278 | 2/824 |
| Cardiac failure chronicCardiac disorders | 1/278 | 0/824 |
| Ischaemic cardiomyopathyCardiac disorders | 1/278 | 0/824 |
| Myocardial ischaemiaCardiac disorders | 1/278 | 0/824 |
| TachycardiaCardiac disorders | 1/278 | 0/824 |
| CholelithiasisHepatobiliary disorders | 1/278 | 0/824 |
| Foot fractureInjury, poisoning and procedural complications | 1/278 | 0/824 |
| MyositisMusculoskeletal and connective tissue disorders | 1/278 | 0/824 |
| Radicular painNervous system disorders | 1/278 | 0/824 |
| Event | Participants With Stage I-III Hip Osteoarthritis (HOA) | Participants With Stage I-III Knee Osteoarthritis (KOA) |
|---|---|---|
| Respiratory tract infectionInfections and infestations | 7/278 | 18/824 |
| Abdominal pain upperGastrointestinal disorders | 2/278 | 12/824 |
| Abdominal discomfortGastrointestinal disorders | 4/278 | 1/824 |
| Back painMusculoskeletal and connective tissue disorders | 4/278 | 2/824 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 4/278 | 9/824 |
| HypertensionVascular disorders | 4/278 | 2/824 |
| HeadacheNervous system disorders | 3/278 | 11/824 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/278 | 5/824 |
| OsteochondrosisMusculoskeletal and connective tissue disorders | 3/278 | 4/824 |
| Age, Continuous(Years) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 60.4 ± 6.9 | 60.3 ± 7.21 | 60.4 ± 6.97 |
| Sex: Female, Male(Participants) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Female | 728 | 240 | 968 |
| Male | 96 | 38 | 134 |
| Race (NIH/OMB)(Participants) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 820 | 278 | 1098 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Pain intensity subscale(Scores on a scale) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 61.48 ± 16.434 | 60.97 ± 17.321 | NA ± NA |
| Other symptom subscale(Scores on a scale) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 62.25 ± 18.034 | 61.17 ± 17.691 | NA ± NA |
| Functional activity of the joint subscale(Scores on a scale) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 61.46 ± 10.599 | 65.57 ± 16.515 | NA ± NA |
| Life quality subscale(Scores on a scale) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 44.99 ± 17.009 | 46.79 ± 17.507 | NA ± NA |
| Patient satisfaction assessment(Scores on a scale) | Participants With Stage I-III Knee Osteoarthritis (KOA) | Participants With Stage I-III Hip Osteoarthritis (HOA) | Total |
|---|---|---|---|
| Mean | 3.2 ± 0.5 | 3.1 ± 0.42 | 3.1 ± 0.48 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Mar 2020, 27 months.
Results were first posted in Oct 2021, 1 year 6 months after primary completion.
Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's 27 months is below that.
Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.